Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207031010

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 16:00:00 2024-05-21 EDT			5-day change	1st Jan Change
0.236 ^USD	-4.88%		+4.52%	-84.37%

04-16	Calidi Biotherapeutics Prices $6.1 Million Offering	MT
03-21	H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating	MT

Calidi Biotherapeutics, Inc. announced a financing transaction

November 31, 2023

Calidi Biotherapeutics, Inc. announced that it will receive $341,250 in funding on November 1, 2023. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics Prices $6.1 Million Offering	04-16	MT
H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating	03-21	MT
Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding	03-20	CI
Calidi Biotherapeutics, Inc. announced that it expects to receive $3.5 million in funding	03-07	CI
Sector Update: Health Care Stocks Firmer Late Afternoon	02-07	MT
Calidi Biotherapeutics to Sell Common Stock	02-07	MT
Calidi Biotherapeutics, Inc. announced that it has received $1 million in funding	01-25	CI
Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments	01-08	CI
Calidi Biotherapeutics, Inc.(NYSEAM:CLDI) added to S&P TMI Index	12-18	CI
Calidi Biotherapeutics Announces Directorate Changes	12-12	CI
Calidi Biotherapeutics, Inc. announced that it expects to receive $25 million in funding from Yorkville Advisors Global LP	12-09	CI
Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board	12-05	CI
HC Wainwright Starts Calidi Biotherapeutics With Buy Rating, $11 Price Target	11-22	MT
Calidi Biotherapeutics Gets US Patent for Cancer Treatment Technology Platform	11-20	MT
Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting	11-03	CI
Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment	11-01	CI
Calidi Biotherapeutics, Inc. announced a financing transaction	10-31	CI
Calidi Biotherapeutics Names Andrew Jackson as Chief Financial Officer	23-10-30	MT
Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer	23-10-30	CI
Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer	23-10-27	CI
Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer	23-10-27	CI
Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director	23-10-24	CI
Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board	23-10-16	CI
Baird Starts Calidi Biotherapeutics With Outperform Rating, Price Target is $9	23-10-09	MT
Calidi Biotherapeutics Announces Primary, Secondary Offering of Shares, Warrants	23-10-06	MT

Chart Calidi Biotherapeutics, Inc.

Duration

Period

More charts

Company Profile

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Annual Meeting - Abstract No: 2553

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.2481 USD

Average target price

3.25 USD

Spread / Average Target

+1,209.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CALIDI BIOTHERAPEUTICS, INC.	-84.37%	12.15M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	115B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.31B
ARGENX SE	-3.99%	21.6B
BEIGENE, LTD.	-7.19%	18.23B
WUXI APPTEC CO., LTD.	-39.93%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.26B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.37B
LEGEND BIOTECH CORPORATION	-28.60%	8.28B

Bio Therapeutic Drugs